First in Human of Single and Multiple Doses of MOR106
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation, phase I study for
the assessment of safety, tolerability and pharmacokinetics of single ascending doses of
MOR106 in healthy male subjects and multiple ascending doses in subjects with moderate to
severe atopic dermatitis.